IntelMed — Medical Intelligence by Airfinity

Evidence-led medical intelligence for Disease X

IntelMed delivers a comprehensive, evidence-led medical intelligence capability across Disease X. It integrates a curated fortnightly insights feed, advanced publication tracking and filtering, structured trial monitoring, and real-time digital opinion leader analysis. Together, these modules provide a connected view of the evolving evidence landscape, enabling faster, more informed strategic decision-making.

Fortnightly insights

Ranked items per edition with analyst commentary

New publications

+14

Added in the past 2 weeks

487 total tracked

Active tracked trials

New or updated in the past 2 weeks

42 total tracked

Expert posts monitored

+38

New KOL / DOL posts in the past 2 weeks

1,204 total monitored

At-a-glance module summary

Click any card to drill down

Top insight →

Newsfeed

Candidate A label expansion highlights Disease X treatment momentum

Regulatory • 25 Oct 2025 • Rank #1

Strategic implication: reinforces differentiation and shifts the standard of evidence expected for Candidate A therapies in Disease X.

Publications →

Last 2 weeks

Post-hoc

RWE

Guidelines

Pooled data

Trial tracker highlights →

Trials

Academic head-to-head lifestyle intervention study in Disease XEndpoint-rich primary outcomes

Recruiting

Investigator-led RWE intensification trial in Disease XPrimary endpoint, adherence, discontinuation

Active

Phase 4 long-term adherence studyPersistence and patient-reported outcomes

Follow-up

Digital opinion leader trend →

DOL

Discussion share is shifting toward holistic Disease X management, with growing conversation on patient pathways and real-world implementation.

Active filters Study type: All ✕ Candidate: All ✕ Topic: All ✕

Publication volume by study type over time

Study type breakdown · 487 total

Post-hoc

200

RWE

161

Guidelines

Pooled data

Emphasis on post-hoc and RWE reflects the platform's level-down intelligence mandate — capturing evidence typically missed by CI.

Analyst picks

Curated by the Airfinity medical intelligence team · updated fortnightly

Analyst pick

Post-hoc analysis of Candidate A and baseline risk stratification in Disease X

The Lancet • 14 Mar 2026

Explores heterogeneity of treatment effect across risk bands in Disease X and highlights potential segmentation opportunities for medical narrative development.

Why this matters

"Published without a press release and missed by all major CI trackers. The subgroup signal here directly challenges current patient selection assumptions and is already driving debate among high-influence KOLs."

Show more ⌄

Analyst pick

Real-world persistence with Candidate B in Disease X

Journal of Disease X Research • 10 Mar 2026

Assesses persistence, discontinuation drivers and regional practice variation in Disease X, with relevance for patient pathway and transformation-of-care monitoring.

Why this matters

"Real-world persistence data is increasingly used in HTA submissions and formulary negotiations. This study covers five markets and its discontinuation findings contradict the trial-based narrative — a significant tension worth tracking."

Show more ⌄

Analyst pick

Country-level Disease X guideline update incorporating comorbidity management

National Guideline • 06 Mar 2026

Introduces broader treatment escalation language, including early intensification in high-risk patients and stronger positioning of patient-reported outcomes.

Why this matters

"Country-level guideline updates often precede regional formulary changes by 6–12 months. The new escalation language here is notably aligned with the evidence base for Candidate A — monitor for access implications."

Show more ⌄

Analyst pick

Pooled analysis of treatment durability and key disease markers in Disease X

Disease X Review • 03 Mar 2026

Connects durability signals to secondary disease outcomes in Disease X, useful for evidence synthesis and publication landscape discussions.

Why this matters

"Pooled analyses across seven trials carry significant weight in benefit-risk discussions. The durability findings here will likely be cited in upcoming HTA dossiers — early awareness gives medical affairs a preparation advantage."

Show more ⌄

All publications

487 publications

Title ↕	Study type ↕	Candidate	Journal	Author	Date ↕	Topic

Trial type: Academic / Phase 4 Status: Recruiting, Active Endpoints: Primary, Secondary, PRO, Safety Therapeutic class: All

Trial pipeline timeline start → estimated completion · coloured by status

Recruiting Active Follow-up Completed

Q1 '24Q3 '24Q1 '25Q3 '25Q1 '26Q3 '26Q1 '27

Today

INVEST-001

PATH-DX RWE

STEP-P4

RESOLVE-DX

PIONEER-AC

SUSTAIN-P4

CLARITY-RWE

HORIZON-AC

PERSIST-DX

ACCESS-EU

PATHWAY-4

SIGNAL-IIT

Endpoint co-occurrence heatmap how often endpoints appear together · darker = more frequent

Low

High

Endpoint momentum frequency in new trials · last 6 months vs prior 6 months

PRO / patient-reported

↑ 74%

Biomarker response

↑ 58%

Persistence / adherence

↑ 46%

Quality of life (QoL)

↑ 38%

Disease progression

→ +9%

Primary efficacy

→ +4%

Safety / tolerability

↓ 12%

MACE / CV events

↓ 31%

Signal: PRO and biomarker endpoints are rapidly entering trials where they were previously absent — a leading indicator of how the evidence standard is shifting.

Endpoint adoption over time % of new trials including each endpoint · rolling 6-month window

Tracked trial dataset

Tagged endpoints and key metadata fields · 42 tracked trials

Trial	Status	Type	Population	Endpoints	Est. completion	Source
INVEST-001 Investigator-led Disease X trial	Recruiting	Academic / Interventional	Adults with Disease X at elevated risk	Primary endpoint, secondary outcomes, safety	Apr 2027	ClinicalTrials.gov
PATH-DX RWE Non-industry intensification study	Active	Real-world / Academic	Adults with uncontrolled Disease X	Primary endpoint, adherence, persistence, PRO	Jun 2027	EU CTR
STEP-P4 Phase 4 long-term outcomes	Follow-up	Phase 4	Adults with Disease X — maintenance phase	Primary outcomes, treatment maintenance, discontinuation	Sep 2026	Journal / Registry
RESOLVE-DX Academic head-to-head Candidate A vs B	Recruiting	Academic / Interventional	Adults with moderate-to-severe Disease X	Primary endpoint, comparative effectiveness, PRO	Dec 2026	ClinicalTrials.gov
PIONEER-AC Academic early intervention study	Active	Academic / Interventional	Treatment-naïve Disease X patients, early stage	Disease progression, biomarkers, quality of life	Feb 2027	ClinicalTrials.gov
SUSTAIN-P4 Phase 4 persistence and adherence	Follow-up	Phase 4	Adults completing 12-month Candidate A treatment	Long-term persistence, tolerability, discontinuation drivers	Dec 2026	EU CTR
CLARITY-RWE Real-world treatment sequencing study	Active	Real-world / Registry	Disease X patients across 5 EU markets	Treatment sequencing patterns, adherence, outcomes	Jul 2026	EU Registry
HORIZON-AC Investigator-led comorbidity study	Recruiting	Academic / Observational	Disease X patients with ≥2 comorbidities	Comorbidity burden, care pathway utilisation, PRO	Feb 2027	ClinicalTrials.gov
PERSIST-DX Phase 4 — real-world persistence	Completed	Phase 4	Adults initiating Candidate B in routine care	12-month persistence, discontinuation, tolerability	Sep 2025	Journal / Registry
ACCESS-EU Non-industry access and equity study	Active	Observational / Non-industry	Disease X patients across EU5 + UK	Access rates, formulary uptake, socioeconomic factors	Sep 2026	EU CTR
PATHWAY-4 Care pathway redesign evaluation	Follow-up	Phase 4 / Health systems	Disease X patients in redesigned care pathways	Time to treatment, outcomes, patient experience, cost	Oct 2026	NHS Registry
SIGNAL-IIT Investigator-initiated biomarker study	Recruiting	Academic / Interventional	Disease X patients with specific biomarker profile	Biomarker-stratified response, PRO, safety	Mar 2027	ClinicalTrials.gov

Overview

Evidence-led medical intelligence for Disease X

At-a-glance module summary

Top insight →

Candidate A label expansion highlights Disease X treatment momentum

Publications →

Trial tracker highlights →

Digital opinion leader trend →

Insights Feed

Regulatory approval granted for Candidate A in Disease X — high-risk patient population

Candidate B receives expanded approval for Disease X — comorbid patient population

Post-hoc analysis reveals differential treatment response by disease severity subgroup — missed in primary trial readout

Updated international clinical guidelines recommend earlier treatment initiation in Disease X

Large real-world evidence study confirms long-term persistence advantage for Candidate A over Candidate B

Post-hoc analysis identifies high-responding patient subgroup with distinct baseline characteristics in Disease X

National HTA body issues positive reimbursement recommendation for Candidate A in Disease X

Investigator-led academic trial reports novel findings on Disease X disease progression in treatment-naïve patients

Pooled analysis confirms consistent safety and tolerability profile for Therapy Class A across Disease X trials

Digital opinion leaders increasingly debating patient pathway redesign and access barriers in Disease X

Publications

Publication volume by study type over time

Study type breakdown · 487 total

Analyst picks

Post-hoc analysis of Candidate A and baseline risk stratification in Disease X

Real-world persistence with Candidate B in Disease X

Country-level Disease X guideline update incorporating comorbidity management

Pooled analysis of treatment durability and key disease markers in Disease X

All publications

Trial Tracker

Trial pipeline timeline start → estimated completion · coloured by status

Endpoint co-occurrence heatmap how often endpoints appear together · darker = more frequent

Endpoint momentum frequency in new trials · last 6 months vs prior 6 months

Endpoint adoption over time % of new trials including each endpoint · rolling 6-month window

Tracked trial dataset

Digital Opinion Leaders

Topic post volume over time weekly post count per topic · last 12 weeks

Trending topics by post volume · last 2 weeks vs previous 2 weeks

Latest posts

Posts

Podcast Library

No podcasts saved yet

Generate AI Podcast

Generating your podcast…

Your podcast is ready